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Glioblastoma cells with stem-like properties control brain tumour growth and recurrence. Here, we show that endogenous neural
precursor cells perform an anti-tumour response by specifically targeting stem-like brain tumour cells. In vitro, neural precursor
cells predominantly express bone morphogenetic protein-7; bone morphogenetic protein-7 is constitutively released from neuro-
spheres and induces canonical bone morphogenetic protein signalling in stem-like glioblastoma cells. Exposure of human and
murine stem-like brain tumour cells to neurosphere-derived bone morphogenetic protein-7 induces tumour stem cell differen-
tiation, attenuates stem-like marker expression and reduces self-renewal and the ability for tumour initiation. Neurosphere-
derived or recombinant bone morphogenetic protein-7 reduces glioblastoma expansion from stem-like cells by down-regulating
the transcription factor Olig2. In vivo, large numbers of bone morphogenetic protein-7-expressing neural precursors encircle
brain tumours in young mice, induce canonical bone morphogenetic protein signalling in stem-like glioblastoma cells and can
thereby attenuate tumour formation. This anti-tumour response is strongly reduced in older mice. Our results indicate that
endogenous neural precursor cells protect the young brain from glioblastoma by releasing bone morphogenetic protein-7, which
acts as a paracrine tumour suppressor that represses proliferation, self-renewal and tumour-initiation of stem-like glioblastoma
cells.
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Introduction
Neural stem and precursor cells of the adult brain contribute to
plasticity in the hippocampus and may provide a cellular source for
brain repair (Zhao et al., 2008). However, the stem cell niches
may also be the point of origin for highly aggressive brain tu-
mours, namely glioblastoma (Holland, 2001; Sanai et al., 2005).
A subpopulation of glioblastoma cells with stem-like properties
probably controls the course of pathology and may also account
for tumour-relapse (Galli et al., 2004; Kondo et al., 2004; Singh
et al., 2004). These stem-like brain tumour initiating cells [previ-
ously defined by others as glioma stem cells (GSC); Clarke et al.,
2006] are characterized by their potential for self-renewal, main-
tenance of a cellular hierarchy and increased tumourigenicity, as
compared to bulk tumour cells (Stiles and Rowitch, 2008; Jordan,
2009). GSCs can be identified in primary patient material and from
various glioblastoma cell cultures by a range of different markers
(Singh et al., 2004; Bleau et al., 2009; Son et al., 2009), of which
prominin-1 (CD133) is most commonly used (Stiles and Rowitch,
2008). We and others have previously established that endogen-
ous neural precursor cells from the subventricular zone and white
matter migrate towards experimental glioblastoma (Glass et al.,
2005; Assanah et al., 2006, 2009; Walzlein et al., 2008). Here
we show that bone morphogenetic proteins (BMPs), which control
neurogenesis and gliogenesis in the subventricular zone (Lim et al.,
2000; Colak et al., 2008), co-function as paracrine tumour sup-
pressors in the CNS. Neural precursor cells release BMP7, which
down-regulates Olig2 in stem-like glioblastoma cells and attenu-
ates the tumourigenicity of GSCs. This anti-tumour response is
efficient in young brains but declines with ageing.
Materials and methods
Animals
All animals were handled according to governmental and internal
(Max Delbru¨ck Center) rules and regulations. Wild-type C57BL/6
and non-obese diabetic-severe combined immunodeficiency mice
(Charles River Breeding Laboratories; Scho¨neiche, Germany) were
housed with a 12 h light/dark cycle and received food ad libitum.
Nestin-green fluorescent protein (GFP), BMP7-lacZ animals and surgi-
cal procedures were described previously (Godin et al., 1998; Glass
et al., 2005; Walzlein et al., 2008).
Cell culture
The human glioblastoma cells GBM1 (previously designated
NCH421K), GBM2 (also designated B4), GBM3 (previously designated
NCH441) and GBM4 (previously designated NCH644) were derived
from tumour resections. Mouse astrocytoma cells were obtained from
the National Cancer Institute, NCI-Frederick (MD, USA). All brain
tumour cells were maintained as described for neurospheres below.
Mouse neurospheres were gained from the microdissected and dis-
sociated subventricular zone, and were propagated in neurobasal
medium containing supplement (B27), growth factors (20 ng/ml epi-
dermal and fibroblast growth factors from PeproTech, Hamburg,
Germany) and additives (0.2 mM glutamine, 100 U/ml penicillin and
100 mg/ml streptomycin; from Sigma, St. Louis, MO, USA). Microglia
(Hoffmann et al., 2003), astrocytes (Pivneva et al., 2008) and neurons
(Chirasani et al., 2009) were all cultivated as described.
Lentiviral vectors
Retroviral vectors for the expression of GFP, Olig2-IRES-GFP or
Olig2VP16-IRES-GFP have been described previously by others
(Hack et al., 2005). These vectors were pseudotyped with the vesicu-
lar stomatitis virus-G envelope to generate lentiviral expression vectors.
Flow cytometry
Fluorescence-activated cell sorting analysis was carried out on a LSR II
(BD Biosciences, Erembodegem, Belgium). Cell sorting was carried out
using a fluorescence-activated cell sorting-Aria-II (BD Biosciences).
Antibodies for murine CD133, human CD133 and human isotype con-
trol were all from Miltenyi Biotech (Bergisch Gladbach, Germany).
Mouse isotype control was from R&D Systems (Heidelberg,
Germany). Antibodies for BMP-receptor Ib, BMP-receptor II and iso-
type controls were from RnD Systems, (Wiesbaden, Germany). Data
were analysed using CellQuest and FACSDiva (BD Biosciences) and
FlowJo software (Treestar, Ashland, OR, USA).
Enzyme-linked immunosorbent assay
The Quantikine BMP7 enzyme-linked immunosorbent assay kit was
purchased from R&D-Systems, used according to the manufacturer’s
instructions and analysed using an Infinite-M200 plate reader (Tecan,
Mainz, Germany).
Cytotoxicity assay
Cell death was studied using the Cytotox-Fluor kit from Promega
(Mannheim, Germany) according to the manufacturer’s instructions.
Immunohistochemistry
The paraformadehyde perfused cryoprotected brains were rapidly
frozen in dry ice and mounted onto a sliding microtome. 40 mm
thick sections were incubated for 48 h at 4C with relevant primary
antibodies (Kempermann et al., 2003; Glass et al., 2005). Antibody
against p-Smad1/5/8 was from Abcam (Cambridgeshire, UK), antibo-
dies for vimentin (clone V9), BMP2/4 and BMP7 were from Santa
Cruz Biotechnology, Heidelberg, Germany. All other antibodies have
been described previously (Glass et al., 2005; Walzlein et al., 2008).
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Microscopy
For confocal microscopy (LSM5 EXITER, from Zeiss, Jena, Germany)
we used appropriate gain and black level settings (determined on con-
trol tissues stained with secondary antibodies alone). All confocal
images were taken with a 40 magnification objective. Fluorescence
microscopy for rhodamine-red labelled vimentin and diaminobenzidine
labelled p-Smad1/5/8 were recorded as single images with a Zeiss
Axioplan microscope, and images were overlaid using Photoshop-CS
software (Adobe, San Jose, CA, USA).
Reverse transcriptase polymerase chain
reaction
RNA was isolated by using the RNAeasy-kit from Qiagen (Hilden,
Germany); all buffers and enzymes were purchased from Invitrogen
(Karlsruhe, Germany) and oligonucleotides were from MWG-Biotech
(Ebersberg, Germany). First-strand complementary DNA was synthe-
sized with Moloney murine leukaemia virus reverse transcriptase using
1 mg RNA and oligo dT primer; gene-specific primers were used as
described by others (Piccirillo et al., 2006).
Real-time polymerase chain reaction
Total RNA of cultured cells was isolated using Trizol (Invitrogen) and
5 mg total RNA was reverse transcribed using Superscript II (Promega),
according to the instructions by the manufacturers. Quantitative
real-time polymerase chain reaction (PCR) was performed on the
iCycler IQ 5 multicolour real-time detection system (Bio-Rad,
Munich, Germany), using absolute SYBR green fluorescein (ABgene,
Hamburg, Germany). Oligonucleotides were purchased from
Invitrogen.
A normalized complementary DNA panel of pathologist-verified
human brain tumours (OriGene Technologies, Inc., Rockville, MD,
USA) was used to probe for Olig2 and Bmp7 transcript levels by
quantitative real time PCR.
Western blot
Cells were lysed in HEPES-sodium-Triton-glycerol-buffer [20 mM
HEPES pH 7.5, containing 150 mM NaCl, 1% (w/v) Triton X-100
and 10% (w/v) glycerol]; the protein lysate was subjected to sodium
dodecyl sulphate polyacrylamide gel electrophoresis and transferred to
polyvinylidene fluoride membranes. Membranes were incubated with
specific antibodies and western blots were developed using the chemi-
luminescence method (GE-Healthcare, Freiburg, Germany). Antibody
for (non-phosphorylated) Smad1/5/8 was from Abcam; antibodies for
p-Smad1/5/8, p-Smad2 and anti-Smad 2/3 were from Cell Signalling,
antibodies for -tubulin and actin were from Sigma, Munich,
Germany.
Statistical analysis
Survival statistics were analysed using MATLAB software (Natick, MA,
USA). Bar diagrams are shown as mean values standard errors of the
mean (SEM). Comparisons among the groups were performed with
the Student’s t-test.
Results
BMP7 is constitutively released from
neural precursor cells
Endogenous and exogenous neural precursor cells migrate to ex-
perimental brain tumours in vivo and fulfill some—as yet un-
defined—tumour suppressor function (Staflin et al., 2004; Glass
et al., 2005; Assanah et al., 2006; Walzlein et al., 2008).
Tumourigenicity of primary brain tumours like glioblastomas is
controlled by GSCs (Jordan et al., 2006; Jordan, 2009) and the
present study indicates that neural precursor cells can specifically
suppress these stem-like glioblastoma cells. In order to investigate
the molecular basis of the anti-tumour effect of neural precursor
cells against GSCs in detail, we used GSC cultures gained from
different primary glioblastoma multiforme resections; information
on glioblastoma patients from which samples were retrieved is
given in Supplementary Fig. 1. These GSCs were maintained
under serum-free conditions in the presence of epidermal and
fibroblast growth factors, formed multi-cellular spheres, were clo-
nogenic, expressed an established set of stem- and progenitor-cell
markers and reverted to an adherent and neuronal/
glial-differentiated phenotype under differentiating conditions
(Supplementary Fig. 1 and Supplementary Table 1). Cultivated
GSCs had genomic features typical for glioblastoma multiforme
and retained the chromosomal aberrations of the parental
tumour (Ernst et al., 2009). GSCs could be highly enriched from
glioblastoma multiforme cultures (93–99% purity), as evidenced
by using CD133 as a GSC marker (Supplementary Fig. 2).
Undifferentiated CD133(+) GSCs had very high tumour initiating
capacity in mice in vivo as compared to their differentiated,
CD133() counterparts. In addition to the primary human glio-
blastoma multiforme cultures (which were investigated in immu-
nodeficient mouse models), we have established purification of
CD133(+) GSCs from a mouse astrocytoma line (GL261 cells)
that is syngenic with our immunocompetent mouse models
(Supplementary Figs. 1 and 2, Supplementary Table 1).
Altogether, we established that CD133 is a valid GSC marker in
all our tumour cell cultures, since the CD133(+) but not the
CD133() brain tumour cells had capacity for self-renewal, main-
tained a cellular hierarchy and had increased tumourigenic poten-
tial (Stiles and Rowitch, 2008).
Various BMPs were previously detected in the neural stem cell
niche (Lim et al., 2000; Colak et al., 2008) and recombinant
BMP2 or BMP4 may be of clinical use against GSCs (Piccirillo
et al., 2006; Lee et al., 2008). We screened BMP-expression in
neural precursor cells in order to identify BMPs that may function
as GSC-specific tumour-suppressors in the CNS. We compared the
expression levels of all brain related BMPs: BMP1, BMP2, BMP3,
BMP4, BMP5, BMP6, BMP7 and BMP8b (Mehler et al., 1997;
Ebendal et al., 1998) in murine astrocytoma, in murine GSCs
(see Supplementary material and Wu et al., 2008), in murine
neurospheres and in differentiating neurospheres (cells undergoing
differentiation into astrocytes, oligodendrocytes and neurons) by
using quantitative real-time PCR. We found that BMP7 is the
predominant BMP in neurospheres and that BMP7 is more
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strongly expressed in neurospheres than in any other sample
investigated (Fig. 1A).
Our enzyme-linked immunosorbent assay showed that BMP7-
protein is abundant in neurospheres, but not in astrocytes, micro-
glia or neurons. Migratory polysialic acid-neural cell adhesion
molecule-positive neural precursor cells in particular contain
BMP7 (Fig. 1B). We observed that the BMP mRNA expression
profile was in agreement with BMP-protein release from neural
precursor cells and found that BMP7, but not BMP2 or BMP4,
was constitutively released at a detectable level from neural pre-
cursor cells (Fig. 1C). Altogether our data show that the migratory
fraction of neural precursor cells pre-dominantly expresses and
constitutively releases BMP7.
Neural precursor cell-released BMP7
induces canonical BMP signalling and
differentiation in stem-like glioblastoma
cells
Primary human glioblastoma cells, which were highly enriched in
CD133(+) GSCs (GBM1, previously designated NCH421K, see
Supplementary Fig. 1), express the type-I and type-II
BMP-receptors (BMP-receptor I, with the Ia and Ib subtype and
BMP-receptor II; Fig. 2A), which are both necessary for BMP
signalling (Massague, 2000; Lee et al., 2008). Likewise, FACS-
analysis revealed that CD133 positive GSCs express BMP-receptor
Ib and BMP-receptor II on the plasma-membrane (Supplementary
Fig. 3A). Western blotting showed that neural precursor
cell-conditioned medium and recombinant BMP7 activate BMP
signalling in GSCs (Fig. 2B; phosphorylation of Smad1/5/8 protein;
p-Smad1/5/8; Massague, 2000). Smad-phosphorylation is rapidly,
within 15 min and peaking at 30 min, induced in GSCs
(Supplementary Fig. 3B). The selective BMPR-I antagonist
compound C (also termed dorsomorphin; Yu et al., 2008) com-
pletely abrogated the effect of neural precursor cell-conditioned
medium and BMP7 on Smad1/5/8 phosphorylation. Neural pre-
cursor cells induced BMP signalling in GSCs specifically via release
of BMP7 since the effect of neural precursor cell-conditioned
medium on p-Smad1/5/8 could be blocked by a BMP7-specific
blocking antibody, but not with antibodies inhibiting BMP2 or
BMP4 (Fig. 2C). Furthermore, we observed that neural precursor
cell-stimulated p-Smad1/5/8 in GSCs initiates transcription of well
described Smad1/5/8 target genes like DNA-binding protein
Figure 1 BMP7 is predominantly expressed in polysialic acid-neural cell adhesion molecule-positive neural precursor cells in vitro and
constitutively released from neurospheres. (A) Mouse astrocytoma cells (GL261 cells), CD133-expressing mouse astrocytoma cells (GSCs)
and neurospheres were all cultured under neurosphere conditions. Additionally, neurospheres were induced to differentiate
(diff-neurosph.); all cell culture samples were analysed for the expression of the indicated BMPs by real-time PCR; BMP-expression levels
in the cell type with the lowest expression were arbitrarily set as one. Insert in (A): expression of BMP2 and BMP4 is shown by using a
different scale. (B) BMP7 expression was investigated by enzyme-linked immunosorbent assays in mature astrocytes neurons, microglia,
differentiated neural precursor cells (NPCs) and neurospheres. Additionally, polysialic acid-neural cell adhesion molecule (PSA-NCAM) (+)
and () cells were fluorescence-activated cell sorting-purified and BMP7 expression was compared between both samples. (C)
Neurospheres were cultured for 3 days and cell culture supernatants (conditioned medium) was assayed (by enzyme-linked immuno-
sorbent assay) for BMP2, BMP4 and BMP7 (as compared with cell-free medium).
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inhibitor (ID) 1 and ID2 (Massague, 2000), as evidenced by
quantitative PCR (Fig. 2D). BMP7 induced ID1 and ID2 expression
in all GBMs studied (GBM3 cells were previously designated
NCH441 and GBM4 were named NCH644, see also
Supplementary Fig. 1).
Our subsequent experiments indicated that neural precursor
cell-released BMP7 induced differentiation of GSCs. It was readily
observable that GBM-spheres became adherent after stimulation
with neural precursor cell-conditioned medium, which could
be prevented by incubation with an inhibitory antibody for
BMP7, but not for BMP2/4 (Fig. 2E). Furthermore,
neurosphere-conditioned medium and recombinant BMP7
interfered with stem cell-properties in other in vitro assays (inves-
tigating the unlimited capacity for self-renewal and maintenance
of a cellular hierarchy; Jordan et al., 2006; Jordan, 2009). First, we
noted that transient stimulation with neural precursor
cell-supernatant and recombinant BMP7 had a persistent effect
on GSC expansion in a sphere formation assay: we stimulated
GSCs with BMP7 or neural precursor cell-conditioned medium
( compound C, or compound C alone), plated the cells at low
density (100 cells per group) to exclude paracrine signalling and
determined the number of secondary spheres: recombinant BMP7
and neural precursor cell-conditioned medium attenuated second-
ary sphere formation of GSCs (Fig. 2F). Moreover, addition of
Figure 2 Neurosphere derived BMPs induce differentiation and attenuate self-renewal of GSCs. Human glioblastomas (GBM1, GBM2,
GBM3 and GBM4) were cultivated, CD133(+) cells were enriched (to minimum 93% purity) and these GSCs were investigated for neural
precursor cell-induced BMP signalling (A–D), self-renewal and differentiation (E–H). (A) Reverse-transcriptase-PCR shows that GBM1
GSCs express BMP-receptors (BMPR) type-Ia, -Ib and -II. (B) GBM1 GSCs were stimulated with recombinant BMP7 or neural precursor
cell-conditioned medium (CM), with or without the BMP-receptor antagonist compound C (CC); BMP-responses (Smad1/5/
8-phosphorylation) were investigated by western blotting. (C) GBM2 GSCs were stimulated with BMP7 or conditioned medium, with or
without an inhibitory antibody specifically blocking BMP7 (7-inh-AB) or inhibitory antibody with a dual specificity for BMP2 and BMP4 (2/
4-inh-AB); Smad1/5/8-phosphorylation is shown. (D) GBM1 GSCs were stimulated as described in B and analysed by real-time PCR for
expression of the Smad targets DNA-binding protein inhibitor (ID)2; GSCs from GBM2, GBM3 and GBM4 were stimulated with BMP7 (or
left untreated) and analysed for DNA-binding protein inhibitor1 and 2. (E) GBM2 cells undergo morphological changes (i.e. tumour
spheres become adherent) after incubation with conditioned medium; BMP7-, but not BMP2/4-inhibitory antibody, blocks morphological
changes. (F) GBM1 GSCs were treated as in B and formation of secondary spheres was quantified. (G) GBM1 GSCs were stimulated with
BMP7 (or left untreated) and proliferation was quantified. (H) GBM1 GSCs. were stimulated with BMP7 and markers of undifferentiated
(nestin) and differentiated (glial fibrillary acidic protein; GFAP) cells were monitored over a time-course; likewise GBM2, GBM3 and GBM4
were investigated for BMP7 mediated effects on glial fibrillary acidic protein expression. Scale bar in E: 60 mm.
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BMP7 to GSCs reduced proliferation by 40% (Fig. 2G). The
number of undifferentiated, nestin-expressing cells was reduced
by 50% after treating GBM1 cells with BMP7 over a 5 day
time-course (Fig. 2H). Concurrently, we counted a 45% increase
in more differentiated, GFAP expressing cells. Differentiating ef-
fects of BMP7 on GSCs were also seen in all other glioblastoma
multiforme cells studied.
Altogether, this indicates that BMP7 release from neural precur-
sor cells induced canonical BMP signalling and thereby caused
GSC differentiation.
Neural precursor cell-derived
BMP7 attenuates expression of a
glioblastoma stem cell marker and
suppresses GSC function
Expression of CD133 on GSCs correlates with tumour initiating
ability (Singh et al., 2004) and the mean fluorescence intensity
for CD133 (by fluorescence-activated cell sorting) gives a first es-
timate for the abundance of GSC in tumour samples (Piccirillo
et al., 2006; Lee et al., 2008). We exposed both human and
mouse GSCs to neural precursor cell-derived BMP or recombinant
BMP7 and quantified the number of stem-like brain tumour cells
(Fig. 3A–D). Recombinant BMP7 reduced the CD133 fluorescence
level to 45.2, 44.1 and 66.3% of control levels in human-GBM1,
human-GBM2 and mouse–mouse astrocytoma cells, respectively
(Fig. 3A, B and D). The conditioned medium from neurospheres
had an even more profound effect on the CD133 fluorescence
level (reduction to 33.3, 31.3 and 61.4%, respectively, of control
levels in GBM1, GBM2 cells or mouse astrocytoma cells). The
effect of both the recombinant BMP7 and neurosphere condi-
tioned medium was always efficiently antagonized by compound
C and was independent of glioblastoma-cell plating densities.
Compound C alone did not significantly influence CD133 expres-
sion levels. Importantly, we found that the effect of neural
precursor cell conditioned medium on CD133(+) GSCs was
mediated specifically by BMP7 (Fig. 3B). The natural BMP-
antagonist noggin (Massague, 2000) also highly effectively
blocked the neurosphere-conditioned medium induced down-
regulation of CD133 in murine GSC (Fig. 3D). To investigate if
the loss of CD133(+) cells from glioblastoma cultures also reflects
reduced tumourigenicity by GSCs, we performed a survival study.
Therefore, CD133(+) mouse astrocytoma cells were either treated
for five days with recombinant BMP7 or cultivated in control-
medium before inoculation into mice. In comparison to classical
tumour cell models, we only injected 100 cells per animal—this
procedure indicates that the inoculum contained brain tumour cells
with a high potential for tumour-initiation (Singh et al., 2004; Wu
et al., 2008). As shown in Fig. 3E mice survived significantly
longer when inoculated with BMP7 treated cells as compared to
controls.
Altogether our data show that the neural precursor cell-derived
BMP7 can strongly attenuate GSC-marker expression and GSC
function.
Neural precursor cell-derived BMP
attenuates stem-like glioblastoma cells
expansion via down-regulation of Olig2
Our series of experiments indicated that GSCs lose their stem-like
properties after exposure to neural precursor cell-derived BMP7.
The transcription factor Olig2 is expressed in the vast majority of
proliferating high-grade brain tumour cells, Olig2
mRNA-expression levels are increased in glioblastomas (as com-
pared to lower grade tumours; Supplementary Fig. 5); it is ubiqui-
tous in stem-like glioblastoma cells and mandatory for
glioblastoma-initiation (Ligon et al., 2007).
Here, we demonstrate that stimulation of GSCs with neural
precursor cell-derived BMP or with recombinant BMP7
down-regulated Olig2 expression levels, as determined by quanti-
tative PCRs (Fig. 4A); BMP7 efficiently down-regulated Olig2 in all
GBMs studied. To investigate if Olig2 has a direct impact on the
stem-like identity of GSC we used lentiviral gene transfer to over-
express Olig2 or a dominant-negative form of Olig2 (Olig2-VP16)
in GBM1 stem-like glioblastoma cells (Fig. 4B). First, we investi-
gated if Olig2 expression relates to GSC expansion, which would
be in line with its previously suggested function in facilitating pro-
gression through the cell-cycle (putatively by blocking p21waf1
function; Stiles and Rowitch, 2008). Therefore, we transduced
GBM1 cells with vectors for Olig2 or Olig2-VP16 and plated
them at low density. These cells were then maintained in
medium with or without BMP7 for five days, transferred into
fresh (BMP7-free and non-conditioned) stem cell medium and
subsequently secondary sphere formation was monitored. We
observed that addition of BMP7 reduced secondary sphere forma-
tion in GBM1 cells expressing GFP (as expected from our previous
experiments), but that Olig2 over-expression alone increased the
number of spheres by 66% (as compared to controls) and blunted
the effect of BMP7 (Fig. 4C). Furthermore, blockade of Olig2
function (by Olig2-VP16) reduced secondary sphere formation
per se and application of BMP7 did not have any additive
effect. Altogether, these data suggest that Olig2 is a downstream
effector of BMP7 signalling. However, Olig2 does not directly
control CD133 expression and the stem-like identity of GSC, but
has profound effects on the ability of GSCs to expand from single
cells into entire spheres (Fig. 4D). In agreement with this inter-
pretation we observed that the first cell division of BMP7-treated
GSCs and Olig2-VP16 over-expressing GSCs was often abortive
and either directly generated stalled or dead cells, or produced one
apparently normal cell connected with a non-viable cell (not
shown). Hence, our data indicate that the BMP7-mediated reduc-
tion in GSC proliferation and the induction of GSC cell death can
be caused by reduced expression of Olig2.
Neural precursor cells accumulate at
glioblastoma in vivo and express BMP7
Since neural precursor cells can suppress GSCs in vitro and since
brain-endogenous neural precursor cells interact with experimental
brain tumours in vivo (Glass et al., 2005; Walzlein et al., 2008),
we asked whether neural precursor cells may have an intrinsic
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tumour-suppressor function in the CNS. We used mice expressing
GFP under a modified promoter construct for nestin (nestin-GFP
mice) to identify the endogenous neural precursor cells of the
tumour host. We injected fluorescently-labelled, syngenic astrocy-
toma cells into the brain (caudate putamen) of young, postnatal
Day 30, nestin-GFP animals and observed attraction of neural pre-
cursor cells from the subventricular zone to the tumour 14 days
after the injection (at postnatal Day 44; Walzlein et al., 2008). By
performing immunohistochemical colocalization studies and con-
focal microscopy we found that neural precursor cells in the
margin abundantly express BMP7 (Fig. 5A and B); note that the
BMP7-labelling was largely restricted to the rim of nestin-GFP
positive cells (also designated as tumour-border) that surround
an experimental brain tumour in many cellular layers, and was
virtually absent from the main tumour mass and the tumour-free
parenchyma. The BMP7 positive neural precursor cells largely
co-labelled for polysialic acid-neural cell adhesion molecule
(Supplementary Fig. 4A). Polysialic acid-neural cell adhesion mol-
ecule and BMP7 co-expressing neural precursor cells could also be
detected in the anterior subventricular zone (Supplementary
Fig. 4B). In addition, BMP2 and BMP4 were expressed in the
stem cell niche, as already described by others (Colak et al.,
2008), but were very rarely detected at the tumour border
(Supplementary Fig. 4C).
We found that the extent of the neural precursor cell-response
to brain tumours is age-dependent: in younger mice (postnatal
Day 44) many neural precursor cells (95 cells per counting-frame)
accumulated at the tumour, but in older mice (injected with astro-
cytoma at postnatal Day 180 and analysed 14 days after the
operation e.g. postnatal Day 194) only an average number of
Figure 3 Neurosphere-derived BMP7 induced loss of CD133(+) GSCs from human glioblastoma and murine astrocytoma cultures. GSCs
from GBM1, GBM2, GBM3 and GBM4 were stimulated with BMP7 or neural precursor cell-conditioned medium (CM) for 5 days, with or
without the BMP-receptor antagonist compound C (CC); controls (ctrl) were maintained without stimulation or received compound C
alone; CD133() immunolabelling [mean fluorescence intensity (MFI) for CD133] was evaluated by fluorescence-activated cell sorting
(background-label was determined by isotype controls). (A) The GSC marker CD133 is attenuated after stimulation with BMP7 and neural
precursor cell-derived BMPs in GBM1 and GBM2. (B) The neural precursor cell-conditioned medium-induced reduction in CD133 can be
blocked specifically with an inhibitory antibody for BMP7 (7-inh-AB), but not with a blocking antibody for BMP2 and BMP4 (2/4-inh-AB).
(C) CD133(+) GSCs from GBM3 and GBM4 are also reduced by BMP7. (D) Mouse astrocytoma cells were analysed for CD133(+)
expression after addition of BMP7 or neural precursor cell-derived BMPs, as described above; note that noggin antagonized the neural
precursor cell-conditioned medium-induced reduction of CD133(+) GSCs. (E) CD133(+) GSCs were purified from mouse astrocytoma
cultures and either challenged with BMP7 or left untreated. Reduced capacity for tumour initiation was observed in BMP7 treated
astrocytoma after orthotopic implantation of 100 cells into syngenic mice.
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15.5 cells per area were detected (Fig. 5C; see also Glass et al.,
2005; Walzlein et al., 2008). However, the fraction of BMP7-
expressing neural precursor cells remained high in both
age-groups; we observed that 58% of the tumour-associated
nestin positive cells labelled for BMP7 in mice at postnatal Days
44 and 194. The immunohistochemical localization of BMP7 ex-
pression in tumour-associated neural precursor cells was confirmed
in another animal model (Godin et al., 1998). We orthotopically
implanted astrocytoma cells into syngenic mice, which express
b-galactosidase under the promoter for BMP7. The BMP7-related
reporter gene activity was detected in polysialic acid-neural cell
adhesion molecule positive neural precursor cells in the tumour
margin (Fig. 5D).
Taken together our data show that neural precursor cells in the
brain tumour margin express BMP7, which we characterized as a
paracrine tumour suppressor that specifically targets GSCs. The
young brain recruits larger numbers of endogenous neural precur-
sor cells to astrocytomas than the older brain, implying that only in
the young brain neural precursor cells can efficiently suppress
GSCs by activating Smad1/5/8 signalling.
Neural precursor cells induce Smad1/5/8
signalling in GSCs in vivo and reduce
GSC-tumourigenicity
To investigate if tumour-associated neural precursor cells may
have a tumour-suppressive action on GSCs in vivo, we asked
whether neural precursor cells can evoke BMP-specific responses
in human stem like glioblastoma cells. To address this question,
GBM1 cells were inoculated into the brains of immunodeficient
mice (Fig. 6). One group of glioblastoma-recipient mice was
young (inoculated with GBM1 cells at P30 and inspected at post-
natal Day 44; Fig. 6A–D). A second group of tumour-recipients
was older (postnatal Day 194 at the end of the experiment;
Fig. 6E). Four days before ending the experiment, some of the
older mice were additionally injected with neural precursor cells
into the tumour-area. At the end-point of the experiment both
groups had developed glioblastomas, which were inspected for
activated (phosphorylated) Smad1/5/8 (p-Smad1/5/8) in the
GBM1 cells. GBM1 cells were identified by co-labelling with a
human-specific antibody for vimentin [hu-vimentin; a radial glia
marker that is expressed in human CD133(+) stem-like glioblast-
oma cells (Zecevic, 2004; Loja et al., 2009)]. As a control we also
studied animals that received mock-injections.
Adult subventricular neurogenesis requires BMP signalling,
which can be visualized by immunolabelling for p-Smad1/5/8
(Colak et al., 2008). Other brain regions, e.g. the caudate
putamen in both young and old mice, were virtually free of
p-Smad1/5/8 labelling (Fig. 6B and C). However, in young
mice, glioblastoma in the caudate putamen showed intense stain-
ing for p-Smad1/5/8 (Fig. 6C and D) and colocalization with
human-vimentin revealed that p-Smad1/5/8 staining largely origi-
nated from the tumour cells (Fig. 6D). Glioblastoma in older mice
did not exhibit much p-Smad1/5/8 labelling (Fig. 6E), unless the
Figure 4 Neural precursor cell-derived BMP and BMP7 attenuate stem-like glioblastoma cells expansion via down-regulation of Olig2.
(A) GBM1 GSCs were stimulated with recombinant BMP7 or neurosphere conditioned medium (CM) for 5 days, with or without the
BMP-receptor type-Ia and Ib antagonist compound C (CC), respectively; controls (ctrl) were maintained without stimulation or received
compound C alone; then expression of Olig2 was measured by real-time PCR; likewise the expression of Olig2 was measured in GBM2,
GBM3 and GBM4 GSCs with and without stimulation by BMP7. (B) Olig2 expression and function in GSCs were directly manipulated with
lentiviral vectors encoding GFP (control), Olig2 or dominant-negative Olig2 (Olig2-VP16); transduced cells were identified by bicistronic
expression of GFP. (C) GBM1 cells expressing GFP, Olig2 or Olig2-VP16 were purified by fluorescence-activated cell sorting and main-
tained under control conditions or received BMP7 for 5 days, then the capacity for secondary sphere formation in normal medium was
measured. (D) GBM1 cells were transduced as in C, subsequently CD133() surface labelling was measured in GFP expressing cells; note
that Olig2 has virtually no influence on intensity of CD133() labelling.
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older mice had been co-inoculated with neural precursor cells into
the tumour-area. Quantification of p-Smad1/5/8 labelling
suggested that stem-like glioblastoma cells respond to neural pre-
cursor cell-derived BMP in vivo: in postnatal Day 44 mice, many
neural precursor cells accumulate in the tumour-border and induce
BMP signalling in the GBM1 cells; in postnatal Day 180 mice, the
few neural precursor cells in the tumour-vicinity induce very little
Smad1/5/8 phosphorylation; and BMP signalling in glioblastoma
of older mice could be restored after injection of neural precursor
cells into the tumour (indicating that neural precursor cells induce
Smad-1/5/8 activation in GBM1 cells). Mock injections were with-
out effect (Fig. 6F).
Furthermore, we investigated if neurosphere-induced Smad1/5/
8-activation in GSCs would have an effect on tumour initiation
and survival in mice. We added neural precursor cell-conditioned
medium with or without the BMP-receptor antagonist compound
C to GBM1 stem-like glioblastoma cells, left the cells under these
conditions for five days and then implanted 100 cells into brains of
immunodeficient mice. We observed that GBM1 cells that had
received neurosphere conditioned medium alone had a strongly
reduced capacity for tumour-initiation, as compared to human
stem-like glioblastoma cells incubated with neural precursor
cell-conditioned medium plus compound C. Six out of 12 mice
inoculated with GBM1 cells exposed to neural precursor
Figure 5 Endogenous neural precursor cells accumulate at experimental brain tumours and express BMP7. Nestin-GFP mice (aged
postnatal Day 30 or 90) were inoculated with fluorescently labelled or unlabelled syngenic astrocytoma cells. Fourteen days after
tumour-injection [mouse age is now postnatal Day (P) 44 and 194, respectively], brains were inspected for tumour-associated neural
precursor cells and expression of BMPs. (A) GFP-expressing cells accumulate in large numbers at a brain tumour; BMP7 is abundantly
expressed in and immediately around GFP-positive cells and in the tumour border; BMP7 labelling is absent from the normal parenchyma
and from the tumour core; the boxed area is magnified. (B) Optical section obtained by confocal microscopy were processed to generate a
3D view of nestin-GFP(+) cells co-expressing BMP7 in the tumour border. (C) Quantification of the number of neural precursor cells
(NPCs) accumulating at an astrocytoma in young and aged mice (bar diagram) and fraction of tumour-associated neural precursor cells
expressing BMP7, respectively, BMP2 or BMP4. (D) Inoculation of syngenic astrocytoma cells into BMP7-reporter mice (BMP7 promoter
driving the lac-Z gene), revealed that polysialic acid-neural cell adhesion molecule (PSA-NCAM) positive neural precursor cells express
BMP7 in the tumour margin. Scale bars are: 100 mm in A; 5 mm in B; C statistical difference is significant, P50.001.
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cell-conditioned medium survived free of symptoms until the end
of the study (more than 240 days; Fig. 6G). In contrast, all mice
receiving GBM1 cells treated with neurosphere conditioned
medium plus compound C died within an average time of
48 days, All differences in survival time were statistically highly
significant (P50.001).
Overall, our data show that neural precursor cells release BMP
in the tumour margin and can suppress glioblastoma by targeting
GSCs. The data presented here now explain previous observations
by us and others that co-inoculation of neural precursor cells with
human or mouse glioblastoma cells reduces tumourigenicity and
improves survival (Staflin et al., 2004; Glass et al., 2005; Suzuki
et al., 2005; Walzlein et al., 2008).
Discussion
The germinal centres of the CNS are thought to be the point of
origin for primary brain tumours (Holland, 2001; Sanai et al.,
2005; Stiles and Rowitch, 2008). Neural precursor cells are the
mitotically and migratory active cells of the brain and genetic mu-
tations can transform them into a highly proliferative and invasive
Figure 6 Neural precursor cells induce BMP-related Smad-signalling in GBM1 stem-like glioblastoma cells in vivo. Brains of young
[postnatal Day (P) 44] and older (postnatal Day 194) mice were orthotopically implanted with GBM1 cells and inspected for Smad1/5/8
signalling after 14 days of tumour growth (A–E). The extended neural precursor cell (NPC)-induced Smad-signalling was quantified and
the impact of neural precursor cell-derived BMP on glioblastoma-pathology was measured (F and G). (A) Outline of the area for
tumour-inoculation and subventricular zone (SVZ). (B) Immunolabelling for p-Smad1/5/8 in the subventricular zone. (C) P-Smad1/5/8
labelling in the tumour-bearing hemisphere at postnatal Day 44; note that the tumour (boxed-area) but not the surrounding parenchyma
label for p-Smad1/5/8; the boxed area was magnified. (D) The p-Smad1/5/8(+) cells are of human origin (GBM1 cells co-label with a
human-specific antibody for vimentin; hu-vimentin). (E, upper) At postnatal Day 194 very little p-Smad1/5/8 labelling is detectable in
GBM1-cell induced glioblastoma. (E, lower) Older mice were injected with GBM1 cells and (4 days before sacrifice) co-injected with neural
precursor cells (into the glioblastoma), p-Smad1/5/8 labelling at end of experiment is shown. (F) Quantification of the number of
p-Smad1/5/8-labelled GBM1 cells (identified by hu-vimentin) in young mice (postnatal Day 44), old mice (postnatal Day 194) and old
mice substituted with neural precursor cells; mock injections (no injection of cells) served as controls for the substitution with neural
precursor cells in older mice. (G) CD133(+) GSCs were purified from GBM1 and stimulated with neural precursor cell-conditioned medium
(conditioned medium) with or without the BMPR-I antagonist compound C (CC). Reduced capacity for tumour initiation (after orthotopic
implantation of 100 cells into non-obese diabetic-severe combined immunodeficiency mice) was observed only when GBM1 GSCs were
treated with conditioned medium alone. Scale bars are: 20 mm in B and E; 125mm in C; 50 mm in the magnified image; 5mm in D; statistical
difference in F and G is significant, P50.05.
1970 | Brain 2010: 133; 1961–1972 S. R. Chirasan et al.
cellular mass (Holland, 2001). The sub-fraction of glioblastoma
cells with stem cell-like properties may arise either early during
tumourgenesis or may accumulate while the tumour progresses
into more malignant stages (Jordan, 2009); in any case GSCs
appear to control the course of pathology (Gunther et al.,
2008). In extension to this concept, we hypothesize that neural
precursor cells are not only a source of glioblastoma but also serve
as line of defence against glioblastoma—since they can suppress
GSCs.
In our present study we have shown that neural precursor
cells accumulating at brain tumours in the young brain abundantly
express BMP7, but not BMP2 or BMP4. It has been demonstrated
that recombinant BMP2 and BMP4 may function as GSC-specific
glioblastoma therapeutics (Piccirillo et al., 2006; Lee et al., 2008).
Our study suggests the possibility that BMP7 is an endogenous,
GSC-specific anti-tumour factor, which can be therapeutically
useful by the same criteria used for BMP2 and BMP4. Neural
precursor cell-released BMP7 stimulated a canonical BMP response
in stem-like glioblastoma cells, which interfered with all three
key-functions of GSCs (Jordan et al., 2006; Jordan, 2009):
(i) the ability of GSCs to maintain a cellular hierarchy was reduced
(the markers or undifferentiated cells CD133, nestin and
Olig2 were lost, whereas the differentiation marker GFAP
was induced); (ii) the ability for self-renewal was reduced
(attenuated ability to form spheres); and (iii) the potential for
tumour-initiation by murine and human CD133-positive GSCs
was strongly reduced.
The effect of neural precursor cell-conditioned medium was due
to BMP7 since the reduction in GSC number and the induction of
GSC differentiation were blocked by a BMP7 inhibitory antibody;
as well as by compound C, a blocker of canonical BMP signalling
(Yu et al., 2008) and noggin, a natural BMP-antagonist
(Massague, 2000). We found that BMP-release from neural pre-
cursor cells down-regulates Olig2 in GSCs—a transcription factor
that is required for tumour initiation in the CNS (Ligon et al.,
2007)—and thereby reduces tumour expansion. Our data imply
that the BMP-Olig2 signalling axis may have different functions
during physiology or pathology, which are lineage determination
(Lim et al., 2000; Colak et al., 2008), respectively, tumour
suppression.
The subventricular zone is the likely source for primary glioblast-
oma (Marumoto et al., 2009). We speculate that the subventri-
cular zone of younger individuals is intrinsically protected against
transformed stem cells by BMP and especially BMP7-release from
neural precursor cells. However, this intrinsic tumour-suppressor
mechanism is lost with the age-related decline in neurogenesis.
One of the few known risk factors for glioblastoma-development
is ageing. We hypothesize that the older brain may have a higher
propensity to develop primary glioblastomas when the number
of BMP-secreting neural precursor cells is reduced. Additionally,
BMP7 is a target for epigenetic inactivation in high grade primary
brain tumours (Ordway et al., 2006). In our future studies we
will address if BMP7 loss is an early event during gliomagenesis,
which may point to a pro-pathological role for BMP7-silencing
during neoplastic transformation of stem and precursor cells in
the brain.
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